Efficacy of Ixekizumab Alone or Combined with Tirzepatide in Psoriasis Patients with Overweight or Obesity: A Phase 3b Study
By
Mark Lebwohl
Andrew Blauvelt
Cynthia E. Kartman
Cianna Leatherwood
Kenneth B. Gordon
Naveed Sattar
Luis Puig
Joseph F. Merola
Kimberly Siu
Rona Wang
Luna Sun
Ann Leung
Najwa Somani
Maria Jose Rueda
Anabela Cardoso
Mark C. Genovese
April W. Armstrong
Bruce Strober
July 1, 2026
Clinical Scorecard: Efficacy of Ixekizumab Alone or Combined with Tirzepatide in Psoriasis Patients with Overweight or Obesity: A Phase 3b Study
At a Glance
Category Detail
Condition Psoriasis Key Mechanisms Chronic low-grade systemic inflammation with increased inflammatory cytokines. Target Population Adults with moderate to severe plaque psoriasis and overweight or obesity. Care Setting Phase 3b clinical trial.
Key Highlights
Psoriasis prevalence in individuals with overweight or obesity is 60% to 78%. Ixekizumab shows robust skin clearance and safety profile. Tirzepatide demonstrates substantial weight reduction and cardiometabolic improvements. Combination therapy may enhance clinical benefits for psoriasis and obesity. Primary endpoint includes achieving PASI 100 and at least 10% weight reduction. Guideline-Based Recommendations
Diagnosis
Assess comorbidities, including obesity. Use Static Physician Global Assessment (sPGA) and PASI scores for evaluation. Management
Aim for complete skin clearance (PASI 100). Support weight reduction for patients with overweight or obesity. Monitoring & Follow-up
Routine assessment of psoriasis severity and weight-related comorbidities. Risks
Increased risk of treatment discontinuation and developing psoriatic arthritis in patients with obesity. Patient & Prescribing Data
Adults with moderate to severe plaque psoriasis and BMI ≥27.
Ixekizumab administered as 80 mg injections; Tirzepatide initiated at 2.5 mg weekly, adjusted based on tolerance.
Clinical Best Practices
Individualized counseling for diet and exercise. Consider combination therapy for enhanced outcomes in psoriasis and obesity. Related Resources & Content
